Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 264

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 264
---
───────────────────────

                                                            Weighted                           
                                                            average                            
                                                            exercise price (USD$)              
 ───────────────────────────────────────────────────────────────────────────────────────────────
  Outstanding, October 31, 2022      5,254       613.5      $                          450.64  
  Granted                              334      442.22                                 318.81  
  Outstanding, October 31, 2023      5,588      603.12      $                          434.82  
  Expired                             ( 67      720.00                                 533.14  
  Outstanding, October 31, 2024      5,521      601.71      $                          432.38  
  Exercisable, October 31, 2024      5,351      603.50      $                          433.67  

  On May 23, 2023, the Company granted 61 stock options to a consultant of the Company. The options are exercisable at $ 227.09 (CAD$ 315.00) per share. The options expire on May 23, 2033.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  ii)      On June 26, 2023, the Company granted 223 stock options to a consultant of the Company. The 156 options are exercisable at $ 363.35 (CAD$ 504.00) per share and the 67 options are exercisable at...  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  iii)      On July 6, 2023, the Company granted 50 stock options to a consultant of the Company. The options are exercisable at $ 23.40 per share. The options expire on July 6, 2033.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

F-29

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  10.      Stock                

  Additional information regarding stock options outstanding as of October 31, 2024, is as follows:  
 ─────────────────────────────────────────────────────────────────